Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
10.1016/S0140-6736(19)31271-1 Summary Keywords colorectal cancer, gastrointestinal cancer, GLP-1 receptor agonists, liver cancer, meta-analysis, obesity, oncological safety, pancreatic cancer Citation Wali AF, Rangraze I, Khan S, Mufti UB, El-Tanani M and Rizzo M (2026) Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies
The Journal of Clinical Endocrinology & Metabolism, 105(8), e3000e3002
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
Salinas is ready to help you enjoy the full benefits of your weight loss success
First, substantial heterogeneity was observed across the included studies, likely reflecting differences in study design, participant characteristics, GLP-1 receptor agonist types, follow-up duration, and methods used to assess depression outcomes
The American Heart Association defines metabolic syndrome by the presence of three or more of the following risk factors: abdominal obesity, high blood pressure, elevated fasting glucose, high triglycerides, and low HDL cholesterol
US$ 25.57
US$ 21.60
US$ 26.76
US$ 26.55
